Total Credits: 1.0 including 1.0 AOA Category 1-A Credit(s)
** Please note this program was featured in OPSC's 35th Annual Fall Conference, CME by the Bay 2024, held in Monterey, California. If you attended this event in person or purchased the digital edition, you will not qualify for CME credits by participating in the program. **
In this session, we will delve into the how, when, and why these agents are used in a range of health conditions. The GLP-1RA has fundamentally transformed diabetes treatment, now being utilized for both recommended and off-label indications, with more applications on the horizon.
Learning Objectives:
Disclosures:
I have clinical trials with Eli Lilly and Bayer. I have served as an advisor or consultant with Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk. I am involved in the guidelines for the American Diabetes Association (ASOC), Consensus Statement on Diabetes and Liver Disease, 2025 SOC and American Gastroenterology Association, 2021 Guidelines for NAFLD/NASH, 2025 Guidelines for MASLD/MASH.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Osteopathic Physicians and Surgeons of California (OPSC) is accredited by the AOA to provide osteopathic continuing medical education for physicians.
Grievance Policy: Osteopathic Physicians and Surgeons of California (OPSC) strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to OPSC, by calling the OPSC Office at (916) 822-5246 or by email at opsc@opsc.org.
| GLP-1 Receptor Agonists in Diabetes (3.5 MB) | 53 Pages | Available after Purchase |
Dr. Shubrook’s professional work and passion focuses on preparing the primary care workforce to better manage diabetes and optimizing the prevention and treatment of diabetes. After 10 years in primary care, he completed a Diabetes Management Fellowship and has been focusing on care of the patient with diabetes ever since. He served as the Director of an integrated comprehensive diabetes care center and also as the Director of Clinical Research at both Ohio University Heritage College of Osteopathic Medicine (HCOM) and, more recently, Touro University California College of Osteopathic Medicine. He served a the Director of the Diabetes Fellowship Program for Primary Care Physicians at HCOM and looks forward to expanding this training opportunity to new professionals and a new institution. Dr. Shubrook still advises the program at HCOM and serves on a national ad hoc committee of American Association of Clinical Endocrinologists on implementing primary care diabetes training even more broadly. He has served in a number of national roles such as Chair of the Primary Care Advisory Group of the American Diabetes Association and the Chair of the Research Committee of the Guidelines Advantage, collaboration between the American Heart Association, American Cancer Society and the American Diabetes Association. Dr. Shubrook has been NCQA certified throughout his time as a Diabetologist and has helped each of our Fellows achieve this honor.
Having served in both primary care and specialist roles, he is acutely aware of the gaps in the health care system that lead to fragmented and poorly-coordinated and executed care. Further, having been active in measuring quality of care, he is accustomed and very knowledgeable of the clinical shortcomings of clinical practice self-assessment.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|